BR112017022244A2 - métodos para tratar uma hiperglicemia em um indivíduo submetido à quimioterapia, método para tratar uma hiperglicemia em um indivíduo submetido à quimioterapia ou outra terapia de câncer, método para substituir ou aprimorar um efeito de uma dieta que mimetiza jejum em sensibilização de célula cancerígena, e método - Google Patents

métodos para tratar uma hiperglicemia em um indivíduo submetido à quimioterapia, método para tratar uma hiperglicemia em um indivíduo submetido à quimioterapia ou outra terapia de câncer, método para substituir ou aprimorar um efeito de uma dieta que mimetiza jejum em sensibilização de célula cancerígena, e método

Info

Publication number
BR112017022244A2
BR112017022244A2 BR112017022244A BR112017022244A BR112017022244A2 BR 112017022244 A2 BR112017022244 A2 BR 112017022244A2 BR 112017022244 A BR112017022244 A BR 112017022244A BR 112017022244 A BR112017022244 A BR 112017022244A BR 112017022244 A2 BR112017022244 A2 BR 112017022244A2
Authority
BR
Brazil
Prior art keywords
hyperglycemia
treating
subject undergoing
undergoing chemotherapy
mimics
Prior art date
Application number
BR112017022244A
Other languages
English (en)
Inventor
DI BIASE Stefano
D Longo Valter
Original Assignee
Univ Southern California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Southern California filed Critical Univ Southern California
Publication of BR112017022244A2 publication Critical patent/BR112017022244A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112017022244A 2015-04-16 2016-04-18 métodos para tratar uma hiperglicemia em um indivíduo submetido à quimioterapia, método para tratar uma hiperglicemia em um indivíduo submetido à quimioterapia ou outra terapia de câncer, método para substituir ou aprimorar um efeito de uma dieta que mimetiza jejum em sensibilização de célula cancerígena, e método BR112017022244A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562148451P 2015-04-16 2015-04-16
PCT/US2016/028055 WO2016168802A2 (en) 2015-04-16 2016-04-18 Fasting mimicking diet (fmd) and glucose lowering drugs protect normal cells and generate cancer sensitizing conditions in response to standard and high glucose conditions induced by rapamycin and dexamethasone

Publications (1)

Publication Number Publication Date
BR112017022244A2 true BR112017022244A2 (pt) 2018-07-10

Family

ID=57126369

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017022244A BR112017022244A2 (pt) 2015-04-16 2016-04-18 métodos para tratar uma hiperglicemia em um indivíduo submetido à quimioterapia, método para tratar uma hiperglicemia em um indivíduo submetido à quimioterapia ou outra terapia de câncer, método para substituir ou aprimorar um efeito de uma dieta que mimetiza jejum em sensibilização de célula cancerígena, e método

Country Status (14)

Country Link
US (2) US20160303056A1 (pt)
EP (2) EP4299061A3 (pt)
JP (2) JP2018511625A (pt)
KR (1) KR20180002677A (pt)
CN (1) CN107613979A (pt)
AU (1) AU2016248443B2 (pt)
BR (1) BR112017022244A2 (pt)
CA (2) CA2982875C (pt)
HK (1) HK1249858A1 (pt)
IL (1) IL255026A0 (pt)
MX (1) MX2017013133A (pt)
RU (1) RU2734774C2 (pt)
WO (1) WO2016168802A2 (pt)
ZA (1) ZA201707710B (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2017014110A (es) * 2015-05-06 2019-03-28 Univ Southern California Dieta que imita y mejora el ayuno para tratar la hipertensión y trastornos lipídicos.
WO2017142952A1 (en) 2016-02-15 2017-08-24 University Of Southern California Drug combinations and methods to stimulate embryonic-like regeneration to treat diabetes and other diseases
AU2017261723B2 (en) 2016-05-11 2023-02-09 University Of Southern California Fasting mimicking diet (FMD) as an immunoregulatory treatment for gastrointestinal autoimmune/inflammatory diseases.
WO2018102393A1 (en) * 2016-11-30 2018-06-07 Cure Cancer Worldwide Llc System for chemotherapy delivery and method of the same
US11284640B2 (en) * 2017-02-14 2022-03-29 University Of Southern California Fasting mimicking diet
BR112020018564A2 (pt) 2018-03-15 2020-12-29 University Of Southern California Composição probiótica para doença gastrointestinal autoimune e/ou inflamatória, uso de uma dieta que simula jejum para prevenir ou tratar doença gastrointestinal autoimune e/ou inflamatória, e suplemento dietário
US20220400732A1 (en) * 2019-03-21 2022-12-22 Cornell University Anti-fructose therapy for colorectal and small intestine cancers
US20210386106A1 (en) * 2020-06-14 2021-12-16 L-Nutra, Inc. Intermittent fasting bar/drink that maintains and extends the fasting state
EP4180047A4 (de) * 2020-07-10 2024-03-13 Martynova, Elena Anatol'evna Verfahren zur durchführung eines fastenverlaufs für schwerkranke patienten

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2549954C2 (ru) * 2009-10-22 2015-05-10 Юниверсити Оф Саутерн Калифорния Способы и диетологические составы для повышения эффективности и снижения побочных эффектов лечения рака
SG191048A1 (en) * 2010-12-06 2013-07-31 Cure Cancer Worldwide Corp Methods of metabolic targeting cancer cells using che mo- and immunotherapy for treating cancer
MX2015010320A (es) * 2013-02-12 2016-06-02 Univ Southern California Metodos y dietas para proteger contra la quimiotoxicidad y enfermedades asociadas con la edad.
MX2016000102A (es) * 2013-07-01 2016-08-18 Univ Southern California Condicion de ayuno como tratamiento dietetico de la diabetes.
RU2697480C2 (ru) * 2014-03-06 2019-08-14 Юниверсити Оф Саутерн Калифорния Применение режима краткосрочного голодания в сочетании с ингибиторами киназ для усовершенствования традиционной химио-лекарственной эффективности и пригодности и обращения вспять побочных эффектов от киназ в нормальных клетках и тканях

Also Published As

Publication number Publication date
MX2017013133A (es) 2018-09-07
JP2021008491A (ja) 2021-01-28
RU2017136423A (ru) 2019-05-16
WO2016168802A2 (en) 2016-10-20
RU2734774C2 (ru) 2020-10-23
HK1249858A1 (zh) 2018-11-16
CN107613979A (zh) 2018-01-19
KR20180002677A (ko) 2018-01-08
RU2017136423A3 (pt) 2019-09-04
AU2016248443A1 (en) 2017-11-02
EP4299061A3 (en) 2024-02-28
IL255026A0 (en) 2017-12-31
US20210137856A1 (en) 2021-05-13
US20160303056A1 (en) 2016-10-20
ZA201707710B (en) 2019-04-24
AU2016248443B2 (en) 2021-03-18
CA3108664A1 (en) 2016-10-20
CA2982875A1 (en) 2016-10-20
EP4299061A2 (en) 2024-01-03
JP2018511625A (ja) 2018-04-26
EP3283073A4 (en) 2019-02-13
CA2982875C (en) 2021-10-19
EP3283073A2 (en) 2018-02-21

Similar Documents

Publication Publication Date Title
BR112017022244A2 (pt) métodos para tratar uma hiperglicemia em um indivíduo submetido à quimioterapia, método para tratar uma hiperglicemia em um indivíduo submetido à quimioterapia ou outra terapia de câncer, método para substituir ou aprimorar um efeito de uma dieta que mimetiza jejum em sensibilização de célula cancerígena, e método
BR112017023037A2 (pt) aparelho e método para funções virtualizadas em planos de controle e de dados.
BR112017020893A2 (pt) método para o tratamento de câncer
BR112017018954A2 (pt) uso de forma mutante de proteína ras e método para tratar câncer
BR112017020973A2 (pt) método para tratar câncer em um paciente
SG11201606967RA (en) Word alignment score computing apparatus, word alignment apparatus, and computer program
DK3252650T3 (da) Anonymiseringsbehandlingsindretning, anonymiseringsbehandlingsfremgangsmåde og program
ZA201705535B (en) System, method and computer program for an access control system
GB201602422D0 (en) Method of, and apparatus for, testing computer hardware and software
BR112018002427A2 (pt) terapias de combinação para tratamento do câncer
EP3518116A4 (en) METHOD AND APPARATUS FOR LAYERED ACCESS TO A FILE IN A VIRTUALIZATION INSTANCE
BR112018008799A2 (pt) método de prognóstico
GB201602421D0 (en) Method of, and apparatus for, testing computer hardware and software
GB2550070B (en) System and method for computer tomography
GB201511378D0 (en) Apparatus, method and computer program
SG11201702806UA (en) Write request processing method, processor, and computer
GB201511379D0 (en) Apparatus, method and computer program
BR112017014646A2 (pt) método para determinar uma quantidade de interesse em um domínio alvo, aparelho, e programa de computador
BR112017019841A2 (pt) técnica de análise de amostra de tecido
BR112017010005A2 (pt) aparelho e método para considerar localidade espacial no carregamento de elementos de dados para execução
GB201904630D0 (en) Method for thoroughly designing valid and ranked rprimers for genome-scale DNA sequence database
GB201516433D0 (en) Computer apparatus and method for enhancing clinical pathways
SG10201506058UA (en) Method and system for website verification
BR112016003019A2 (pt) composto, composição farmacêutica, método para tratar câncer em um sujeito com necessidade do mesmo, e método para inibir uma desoxicitidina quinase
GB201604215D0 (en) Apparatus, method and computer program

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2719 DE 14-02-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.